Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22908841 | 0.78 | HRH4 (0.31) | HRH4 | |
| SCHEMBL14415970 | 0.67 | HRH4 (0.44) | HRH4 | |
| SCHEMBL20696522 | 0.66 | HPGD (0.42) | HRH4 | |
| SCHEMBL22343509 | 0.66 | HRH4 (0.36) | HRH4 | |
| Hydrochloric Acid SCHEMBL25371613 | 0.65 | HRH4 (0.43) | HRH4 | |
| SCHEMBL14857108 | 0.65 | HRH4 (0.43) | HRH4 | |
| SCHEMBL23713601 | 0.64 | — | — | |
| SCHEMBL26052366 | 0.64 | HRH1 (0.42) | HRH4 | |
| SCHEMBL16264708 | 0.64 | HRH4 (0.42) | HRH4 | |
| SCHEMBL26812529 | 0.64 | HRH4 (0.42) | HRH4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10640511-B2 | Hepatitis B antiviral agents | Enant Pharmaceuticals, Inc. (US) | 2020-05-05 | — | — | US | disclosed |
| US-20190119288-A1 | HEPATITIS B ANTIVIRAL AGENTS | ENANTA PHARM INC (US) | 2019-04-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190119288-A1 | HEPATITIS B ANTIVIRAL AGENTS | HAVCR2, SLC10A1, HDGF | HRH4 2991/4885 |
| US-10640511-B2 | Hepatitis B antiviral agents | HAVCR2, SLC10A1, HDGF | HRH4 2991/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.